Nimotuzumab 50mg
Product Overview
| Generic Name | Nimotuzumab 50mg |
| Brand Name(s) | BIOMAb EGFR® |
| Category | Antineoplastic / Cancer |
| Form | 10ml vial, Sterile injectable monoclonal antibody solution for IV infusion |
| Strength | 50 mg/10 mL vial |
| Therapeutic Class | Anti-EGFR humanised monoclonal antibody; antineoplastic targeted therapy |
| ATC Code | L01FE M1 |
Manufacturing & Regulatory
| Manufacturer | Biocon Biologics |
| GMP Compliance | WHO-GMP |
| COFEPRIS | No active IMSS/CNIS clave found |
| Free Sale Certificate | Yes, available as COPP/CPP |
Logistics & Export
| MOQ | 4 vials |
| Shelf Life | 24 Months |
| Storage | 2–8 °C, protect from light |
| Incoterms | EXW, HS/HSN 30049099 |
| Lead Time | 7 - 10 Business Days |
Documentation Available Upon Request
| Certificate of Analysis (PDF) | Supplied per batch upon request |
| CTD Summary (PDF) | CTD from originator; generic use abbreviated formats |
Special Notes
Nimotuzumab is a humanised anti-EGFR monoclonal antibody used in certain jurisdictions for advanced head and neck squamous-cell carcinoma in combination with radiotherapy and/or chemotherapy; some jurisdictions also reference glioma or other epithelial tumours. It is a biologic oncology medicine requiring specialist supervision, IV administration, and validated 2–8°C cold-chain handling.